SOLICITATION NOTICE
68 -- Multiplex cytokine assay kits
- Notice Date
- 9/4/2009
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90246-NG
- Archive Date
- 10/3/2009
- Point of Contact
- Malinda L Holdcraft, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
holdcram@exchange.nih.gov, cr214i@nih.gov
(holdcram@exchange.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Infections and Immunoepidemiology Branch (IIB) plans to procure on a sole source basis multiplex cytokine assay kits from BioRad, Life Sciences Group, 2000 Alfred Nobel Drive, Hercules, CA 94547. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 325413 and the business size standard is 500 employees. The period of Performance shall be award through 12 months. Chronic inflammation is increasingly recognized as a major etiologic factor for cancer. Recent technologies have enabled the measurement of several cytokines at low cost using low specimen values. Before proceeding with large-scale epidemiologic studies, several aspects of multiplex cytokine assays need to be evaluated. The current procurement will allow the government to conduct an evaluation of the reliability of these technologies, such that future studies can better understand the role of chronic inflammation in cancer etiology. Specifically, the NCI will procure multiplex cytokine assay kits for measurement of 69 cytokines in serum/plasma samples; fourteen kits each of 4 marker matrices—27-plex cytokines, 21-plex cytokines, 12-plex acute phase protein markers, and a 9-plex diabetes panel will be procured from BioRad Life Sciences Group. The government conducted a pilot survey of assay performance across 5 vendors in the market who manufacture multiplex luminex-based cytokine kits.. Performance of multiplex cytokine kits across the 5 vendors was evaluated in terms of 1) the required specimen volume, 2) accuracy of standards provided by the vendors and coefficients of variation in duplicate testing, 3) sensitivity (lower limit of detection for each cytokine), 4) ease of use, and 5) cost. In these evaluations, the government determined that performance of BioRad kits was superior to that of kits from the other vendors. Therefore, the government will utilize multiplex cytokine kits from BioRad for its studies. Bio-Rad is sole supplier of magnetic bead assays for use on the Bio-Plex 200 System. This specification is required to employ automated magnetic washes using the Bio-Plex Pro Wash Station as specified in the Bio-Plex Cytokine Assay Instruction Manual. Incorporating magnetic washes eliminates assay variability, improves sensitivity, and increases productivity requiring less user interaction during assay set-up. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 11:00 a.m. ET on September 18, 2009. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Malinda Holdcraft: holdcram@exchange.nih.gov. It is the vendor’s responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-90246-NG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90246-NG/listing.html)
- Record
- SN01942231-W 20090906/090905001727-dda2219f4fe1e0f74599cdd5bbba92df (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |